Pfizer physician payments totaled $35m for second half of '09

Share this article:
Pfizer paid out $35 million to 4,500 healthcare professionals in the second half of 2009, the company reported.

The figures cover payments, meals and “non-monetary educational items” worth $25 or more and totaling $500 or more, including compensation for speaking and consulting, CME and conducting clinical trials.

Around 44% of the reported payments went to approximately 250 academic medical centers and other research organizations for clinical trials, the company said, accounting for $15.3 million that covered recruitment, coordination and execution of clinical trials and completion of “compliance activities.”

Pfizer reviewed more than 180,000 transactions and consulted patients, researchers and healthcare professionals on the format of its report, which can be viewed at www.pfizer.com/WorkingWithHCP. The company will provide full-year 2010 data on March 31, 2011, and, in compliance with its August 2009 Corporate Integrity Agreement with the Department of Health and Human Services' Office of the Inspector General, will include the value of all financial interactions including non-monetary items such as meals and educational items regardless of value.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...